Dr. Martens plc
DOCS.L · LSE
3/31/2025 | 9/30/2024 | 3/31/2024 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.04 | 0.03 | -0.24 |
| FCF Yield | 0.00% | 5.84% | 21.09% | -3.34% |
| EV / EBITDA | 0.00 | -197.13 | 13.89 | 32.51 |
| Quality | ||||
| ROIC | 0.00% | -1.38% | 13.88% | 3.25% |
| Gross Margin | 0.00% | 63.99% | 66.55% | 54.83% |
| Cash Conversion Ratio | 1.61 | 5.63 | -1.70 | 3.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.95% | 4.83% | 13.57% | 18.56% |
| Free Cash Flow Growth | 0.00% | -83.19% | 492.78% | -173.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -78.84 | 4.02 | 8.20 |
| Interest Coverage | 0.00 | -1.12 | 4.91 | 2.45 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.48 | 0.63 | 0.57 |
| Cash Conversion Cycle | 0.00 | 111.82 | 135.47 | 123.14 |